The NextGene Biosystem is newly founded scientific company, which aggregate variety activities in biomedical research. We are focusing on applied research in the most promising of emerging technologies in biomedicine with emphasis on technology transfer and commercialization to different sphere of our lives. Research an NGB is encouraging partnerships among various disciplines as well as with other educational institutes, private enterprise and government agencies.
NextGene Biosystem , Blagoveshchensk, Amur Region
NextGene Biosystems are licensed for diagnostic activities in the Russian Federation
Laboratory of Cell Technologies, Blagoveshchensk, Amur region
Under the guidance of the head of the Cell Technology Laboratory Anton Yatsenko, laboratory staff Yegor Ustinov and Denis Leonov are working on the development of biological inks for the bioprinting of epithelial tissues. The first prototypes of tissues have already been created and a patent application for the composition of biological ink has been filed, two articles on the results obtained are being prepared for publication. The work is carried out in cooperation with the company IQDEMY, Switzerland, Sierre
Laboratory of PCR and molecular methods, Blagoveshchensk, Amur region
Ksenia Pchelina, Head of the Laboratory of PCR and Molecular Methods, with the staff Pavel Timkin and Valery Derevyannny introduce new methods of molecular diagnostics on the basis of the laboratory with the use of a modern instrument – CytoFlex flow cytometer and thermocyclers with real-time detection of the amplification product. Thanks to these devices, a wide range of scientific and clinical solutions opens
We study how to use, design and synthesis new biomaterials that regulate the gene expression enteracting cells.
We develop clinically significant devices for treatment and diagnostic of trauma injury by utilising engineering principles of fluid flow and mass transfer.
We promote translational aspects of regenerative medicine research.
Our major research interested are in exploring collateral and breast cancer cells in the context of molecular mechanisms responsible for pathological condition and for detecting biomarkers.
NextGene Biosystems offers educational programs in molecular medicine together with Amur State Medical Academy
Recent revolutionary progress in human genomics is reshaping our approach to therapy and diagnosis.
Funded by Amur State Medical Academy and investors, the Amur Stem Cell Bank was established
We are government-approved biomedical company in Russian Federation which provides services for medical tours in South Korea.